Allo-QuadCAR01-T

DRUG3 trials

Sponsors

Avencell Therapeutics Inc., AvenCell Therapeutics, Inc.

Conditions

AML (Acute Myelogenous Leukemia)B-cell LymphomaChronic Lymphocytic LeukemiaHematologic MalignancyLeukemia RelapseLeukemia and LymphomaLymphoma Diffuse Large B-cellLymphoma Receiving CAR-T Therapy

Phase 1

A single-arm, multicenter, open-label, Phase I/II trial of Allo-QuadCAR01-T, an allogeneic CAR-T-cell therapy targeting CD19 and CD20, for the treatment of relapsed or refractory B-cell malignancies

RecruitingCTIS2025-521735-36-00

Avencell Therapeutics Inc.Relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) or chronic lymphocytic leukaemia (CLL)

Start: 2025-12-15Target: 60Updated: 2025-10-27

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

RecruitingNCT07284433

AvenCell Therapeutics, Inc.Leukemia and Lymphoma, Leukemia Relapse, Lymphoma Diffuse Large B-cell +1

Start: 2026-01-06End: 2029-11-02Target: 178Updated: 2026-08-28

Unknown Phase

Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials

Enrolling by invitationNCT07474051

AvenCell Therapeutics, Inc.AML (Acute Myelogenous Leukemia), B-cell Lymphoma, Chronic Lymphocytic Leukemia +2

Start: 2026-01-29End: 2041-01-30Target: 178Updated: 2026-03-16